ArticleiScience2026
Chlorotoxin suppresses melanoma vasculogenic mimicry via LINC01235/miR-128-3p/YY1/ VEGFR2/NRP1 axis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasculogenic mimicry (VM), a process of vascular-like channel formation for nutrient acquisition, drives melanoma metastasis and poor prognosis. We demonstrate that Chlorotoxin (CTX) effectively targets VM in melanoma. In A375 and A2058 cells, CTX dose-dependently inhibits proliferation with IC50 values of 1.0 and 0.8 μM, respectively. Furthermore, sub-lethal CTX (0.4 μM) impairs cell migration and VM tube formation while downregulating VM regulators VEGFR2 and NRP1. Mechanistically, CTX suppresses the long non-coding RNA LINC01235, a competing endogenous RNA that sponges miR-128-3p. CTX-induced downregulation of LINC01235 frees miR-128-3p to target and suppress the transcription factor YY1. This reduction in YY1 diminishes its binding to the VEGFR2 promoter, ultimately decreasing VEGFR2 and NRP1 transcription. Rescue assays confirm that LINC01235 overexpression restores VM capacity. By defining the LINC01235/miR-128-3p/YY1/VEGFR2/NRP1 signaling axis disrupted by CTX, these findings establish the mechanistic basis for CTX as a promising therapeutic agent against aggressive, VM-competent melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.